FDA Panel To Decide Whether New Breast, Prostate Cancer Drugs Are Worth The Risks

FDA Panel To Decide Whether New Breast, Prostate Cancer Drugs Are Worth The Risks FDA staff have expressed concerns about the use of camizestrant to treat metastatic breast cancer and capivasertib for patients with metastatic hormone-sensitive prostate cancer. The Oncologic Drugs Advisory Committee will vote on these two drug applications Thursday. https://kffhealthnews.org/morning-breakout/cancer/